Joseph Klein III Sells 2,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock

Ionis Pharmaceuticals (NASDAQ:IONS) Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction dated Thursday, March 15th. The shares were sold at an average price of $51.13, for a total value of $102,260.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Joseph Klein III also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 29th, Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $46.15, for a total value of $92,300.00.
  • On Wednesday, February 28th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $51.91, for a total value of $155,730.00.
  • On Thursday, February 15th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $48.99, for a total value of $146,970.00.
  • On Tuesday, January 30th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $52.86, for a total value of $158,580.00.
  • On Friday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $50.56, for a total value of $151,680.00.
  • On Friday, December 29th, Joseph Klein III sold 3,000 shares of Ionis Pharmaceuticals stock. The shares were sold at an average price of $50.56, for a total value of $151,680.00.

Ionis Pharmaceuticals stock opened at $40.68 on Friday. The company has a current ratio of 5.20, a quick ratio of 5.15 and a debt-to-equity ratio of 1.45. The company has a market capitalization of $5,101.39, a P/E ratio of 508.50 and a beta of 2.49. Ionis Pharmaceuticals has a one year low of $37.55 and a one year high of $65.51.

Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.02 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.10. Ionis Pharmaceuticals had a negative return on equity of 1.94% and a negative net margin of 1.18%. The company had revenue of $172.00 million for the quarter, compared to analyst estimates of $126.38 million. During the same period in the previous year, the firm earned $0.33 earnings per share. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. equities analysts predict that Ionis Pharmaceuticals will post -0.13 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new position in Ionis Pharmaceuticals in the third quarter valued at approximately $100,000. American International Group Inc. acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at approximately $147,000. Parallel Advisors LLC lifted its stake in Ionis Pharmaceuticals by 60.3% in the third quarter. Parallel Advisors LLC now owns 3,323 shares of the company’s stock valued at $182,000 after buying an additional 1,250 shares during the period. Icon Wealth Partners LLC acquired a new position in Ionis Pharmaceuticals in the fourth quarter valued at approximately $182,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after buying an additional 311 shares during the period. 90.72% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages have recently commented on IONS. ValuEngine lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 28th. BidaskClub lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 28th. Zacks Investment Research raised Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, March 9th. BMO Capital Markets lifted their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, February 28th. Finally, Stifel Nicolaus lifted their price target on Ionis Pharmaceuticals from $55.00 to $57.00 and gave the company a “hold” rating in a research note on Wednesday, February 28th. Four analysts have rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the stock. Ionis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $52.15.

COPYRIGHT VIOLATION WARNING: “Joseph Klein III Sells 2,000 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/insider-selling-ionis-pharmaceuticals-inc-ions-director-sells-2000-shares-of-stock.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply